<DOC>
	<DOC>NCT02847624</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.</brief_summary>
	<brief_title>Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>diagnosed ADPKD total kidney volume of 750 or more</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>